Navigation Links
Gen-Probe to Webcast Three Upcoming Presentations

- Annual Analyst Day for Institutional Investors and Financial Analysts on

November 29 -

- Lazard's Fourth Annual Health Care Conference on November 27 -

- 19th Annual Piper Jaffray Health Care Conference on November 28 -

SAN DIEGO, Nov. 15 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will webcast its annual meeting with institutional investors and financial analysts in New York on Thursday, November 29, 2007, at approximately noon Eastern Time. The event will feature presentations on Gen-Probe's current business and future growth strategies by several Company executives. The meeting and webcast will conclude at approximately 3:30 p.m. Eastern Time.

In addition, the Company will present at the Lazard Capital Markets Fourth Annual Health Care Conference in New York on Tuesday, November 27, 2007 at approximately 4:30 p.m. Eastern Time, and at the 19th Annual Piper Jaffray Health Care Conference in New York on Wednesday, November 28, 2007 at approximately 10:30 a.m. Eastern Time.

Live webcasts of each event may be accessed on the investment information section of the Company's web site at Replays of the webcasts will be available on the same web site for 30 days following the events.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 24 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended September 30, 2007, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Paula Izidoro

Investor Relations


SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
2. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
3. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
4. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
5. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
6. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
9. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
10. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
11. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):